Correlation Between Sera Prognostics and Aclaris Therapeutics

Can any of the company-specific risk be diversified away by investing in both Sera Prognostics and Aclaris Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sera Prognostics and Aclaris Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sera Prognostics and Aclaris Therapeutics, you can compare the effects of market volatilities on Sera Prognostics and Aclaris Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sera Prognostics with a short position of Aclaris Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sera Prognostics and Aclaris Therapeutics.

Diversification Opportunities for Sera Prognostics and Aclaris Therapeutics

0.79

Correlation Coefficient

Sera Prognostics  Aclaris Therapeutics

Poor diversification

The 3 months correlation between Sera and Aclaris is 0.79. Overlapping area represents the amount of risk that can be diversified away by holding Sera Prognostics and Aclaris Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aclaris Therapeutics and Sera Prognostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sera Prognostics are associated (or correlated) with Aclaris Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aclaris Therapeutics has no effect on the direction of Sera Prognostics i.e., Sera Prognostics and Aclaris Therapeutics go up and down completely randomly.

Pair Corralation between Sera Prognostics and Aclaris Therapeutics

Given the investment horizon of 90 days Sera Prognostics is expected to under-perform the Aclaris Therapeutics. In addition to that, Sera Prognostics is 1.62 times more volatile than Aclaris Therapeutics. It trades about -0.26 of its total potential returns per unit of risk. Aclaris Therapeutics is currently generating about -0.22 per unit of volatility. If you would invest  248.00  in Aclaris Therapeutics on December 28, 2024 and sell it today you would lose (89.00) from holding Aclaris Therapeutics or give up 35.89% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Sera Prognostics  vs.  Aclaris Therapeutics

Sera Prognostics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sera Prognostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Aclaris Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aclaris Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Sera Prognostics and Aclaris Therapeutics

The main advantage of trading using opposite Sera Prognostics and Aclaris Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sera Prognostics position performs unexpectedly, Aclaris Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclaris Therapeutics will offset losses from the drop in Aclaris Therapeutics' long position.

The idea behind Sera Prognostics and Aclaris Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.